SK46797A3 - New peptides with immunomodulatory effects, preparation method thereof, pharmaceutical compositions containing them and their use - Google Patents

New peptides with immunomodulatory effects, preparation method thereof, pharmaceutical compositions containing them and their use Download PDF

Info

Publication number: SK46797A3
Authority: SK; Slovakia
Prior art keywords: leu; pro; cys; ile; gly
Prior art date: 1994-10-14

Application number

SK467-97A

Other languages

English (en)

Slovak (sk)

Inventor

Hakan Bergstrand

Tomas Eriksson

Kostas Karabelas

Magnus Lindvall

Bengt Sarnstrand

Original Assignee

Astra Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-10-14

Filing date

1995-10-06

Publication date

1997-09-10

1995-10-06 Application filed by Astra Ab filed Critical Astra Ab

1997-09-10 Publication of SK46797A3 publication Critical patent/SK46797A3/sk

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 158
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 60
230000002519 immonomodulatory effect Effects 0.000 title claims description 33
239000008194 pharmaceutical composition Substances 0.000 title claims description 7
238000002360 preparation method Methods 0.000 title abstract description 11
238000000034 method Methods 0.000 claims abstract description 29
238000004519 manufacturing process Methods 0.000 claims abstract 11
150000001413 amino acids Chemical class 0.000 claims description 181
235000001014 amino acid Nutrition 0.000 claims description 149
125000006239 protecting group Chemical group 0.000 claims description 113
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 93
239000000710 homodimer Substances 0.000 claims description 84
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 78
-1 1-methyl-1- (4-biphenylyl) -ethoxycarbonyl Chemical group 0.000 claims description 56
125000000524 functional group Chemical group 0.000 claims description 46
210000004899 c-terminal region Anatomy 0.000 claims description 38
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 34
125000003368 amide group Chemical group 0.000 claims description 33
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 29
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 28
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 27
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 25
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 25
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 24
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 24
125000000217 alkyl group Chemical group 0.000 claims description 18
125000003277 amino group Chemical group 0.000 claims description 17
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
125000004432 carbon atom Chemical group C* 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 15
239000003795 chemical substances by application Substances 0.000 claims description 14
239000004480 active ingredient Substances 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 10
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 9
239000000178 monomer Substances 0.000 claims description 9
230000015572 biosynthetic process Effects 0.000 claims description 8
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 8
239000004927 clay Substances 0.000 claims description 7
239000000539 dimer Substances 0.000 claims description 5
239000007790 solid phase Substances 0.000 claims description 3
KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 claims description 2
108010077515 glycylproline Proteins 0.000 claims description 2
125000001424 substituent group Chemical group 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 claims 7
229910052799 carbon Inorganic materials 0.000 claims 6
150000008574 D-amino acids Chemical class 0.000 claims 3
230000007717 exclusion Effects 0.000 claims 3
239000003937 drug carrier Substances 0.000 claims 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical group C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 1
125000004429 atom Chemical group 0.000 claims 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
229910052760 oxygen Inorganic materials 0.000 claims 1
239000001301 oxygen Substances 0.000 claims 1
230000008569 process Effects 0.000 abstract description 4
239000002955 immunomodulating agent Substances 0.000 abstract description 3
229940121354 immunomodulator Drugs 0.000 abstract description 3
239000000825 pharmaceutical preparation Substances 0.000 abstract description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
201000010099 disease Diseases 0.000 description 15
239000000243 solution Substances 0.000 description 15
235000018417 cysteine Nutrition 0.000 description 13
239000000047 product Substances 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
150000001875 compounds Chemical class 0.000 description 11
230000000694 effects Effects 0.000 description 10
230000028993 immune response Effects 0.000 description 10
239000011347 resin Substances 0.000 description 9
229920005989 resin Polymers 0.000 description 9
238000003786 synthesis reaction Methods 0.000 description 9
INCJJHQRZGQLFC-KBPBESRZSA-N Leu-Phe-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O INCJJHQRZGQLFC-KBPBESRZSA-N 0.000 description 8
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 8
201000009030 Carcinoma Diseases 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
239000000203 mixture Substances 0.000 description 7
238000004128 high performance liquid chromatography Methods 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
239000003826 tablet Substances 0.000 description 6
102000002933 Thioredoxin Human genes 0.000 description 5
238000009833 condensation Methods 0.000 description 5
230000005494 condensation Effects 0.000 description 5
150000001945 cysteines Chemical class 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
230000003211 malignant effect Effects 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
239000000126 substance Substances 0.000 description 5
229940094937 thioredoxin Drugs 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 4
HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
238000004949 mass spectrometry Methods 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000003380 propellant Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
108060008226 thioredoxin Proteins 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
208000030507 AIDS Diseases 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
208000023275 Autoimmune disease Diseases 0.000 description 3
NXTYATMDWQYLGJ-BQBZGAKWSA-N Cys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CS NXTYATMDWQYLGJ-BQBZGAKWSA-N 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
206010011968 Decreased immune responsiveness Diseases 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
206010018338 Glioma Diseases 0.000 description 3
QSQXZZCGPXQBPP-BQBZGAKWSA-N Gly-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)CN)C(=O)N[C@@H](CS)C(=O)O QSQXZZCGPXQBPP-BQBZGAKWSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000000588 Interleukin-2 Human genes 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
MSHZERMPZKCODG-ACRUOGEOSA-N Phe-Leu-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 MSHZERMPZKCODG-ACRUOGEOSA-N 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 description 3
108010079911 Thioredoxin-disulfide reductase Proteins 0.000 description 3
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
239000002775 capsule Substances 0.000 description 3
108010016616 cysteinylglycine Proteins 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
201000001441 melanoma Diseases 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000005951 type IV hypersensitivity Effects 0.000 description 3
208000027930 type IV hypersensitivity disease Diseases 0.000 description 3
FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
229920000945 Amylopectin Polymers 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
206010006458 Bronchitis chronic Diseases 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
RESAHOSBQHMOKH-KKUMJFAQSA-N Cys-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CS)N RESAHOSBQHMOKH-KKUMJFAQSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
206010012438 Dermatitis atopic Diseases 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
208000032612 Glial tumor Diseases 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 2
IGUOAYLTQJLPPD-DCAQKATOSA-N Leu-Asn-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IGUOAYLTQJLPPD-DCAQKATOSA-N 0.000 description 2
JLWZLIQRYCTYBD-IHRRRGAJSA-N Leu-Lys-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JLWZLIQRYCTYBD-IHRRRGAJSA-N 0.000 description 2
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
102000004316 Oxidoreductases Human genes 0.000 description 2
108090000854 Oxidoreductases Proteins 0.000 description 2
LXUJDHOKVUYHRC-KKUMJFAQSA-N Phe-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CC=CC=C1)N LXUJDHOKVUYHRC-KKUMJFAQSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
ZBAGOWGNNAXMOY-IHRRRGAJSA-N Pro-Cys-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ZBAGOWGNNAXMOY-IHRRRGAJSA-N 0.000 description 2
MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 2
102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
206010070834 Sensitisation Diseases 0.000 description 2
KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
108010067390 Viral Proteins Proteins 0.000 description 2
230000001594 aberrant effect Effects 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000007815 allergy Effects 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
208000011775 arteriosclerosis disease Diseases 0.000 description 2
238000003556 assay Methods 0.000 description 2
201000008937 atopic dermatitis Diseases 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
206010006451 bronchitis Diseases 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
208000007451 chronic bronchitis Diseases 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
230000007123 defense Effects 0.000 description 2
MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical group C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
210000005069 ears Anatomy 0.000 description 2
239000012636 effector Substances 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
230000006870 function Effects 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
150000005828 hydrofluoroalkanes Chemical class 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000009169 immunotherapy Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000011630 iodine Substances 0.000 description 2
229960001614 levamisole Drugs 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
SHDMMLFAFLZUEV-UHFFFAOYSA-N n-methyl-1,1-diphenylmethanamine Chemical group C=1C=CC=CC=1C(NC)C1=CC=CC=C1 SHDMMLFAFLZUEV-UHFFFAOYSA-N 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
201000010198 papillary carcinoma Diseases 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
108020003519 protein disulfide isomerase Proteins 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
230000001177 retroviral effect Effects 0.000 description 2
206010039083 rhinitis Diseases 0.000 description 2
230000008313 sensitization Effects 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
NYJVPTKMDYSZDU-MRNVWEPHSA-N (2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-1-[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid Chemical class CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 NYJVPTKMDYSZDU-MRNVWEPHSA-N 0.000 description 1
DSLBDPPHINVUID-REOHCLBHSA-N (2s)-2-aminobutanediamide Chemical group NC(=O)[C@@H](N)CC(N)=O DSLBDPPHINVUID-REOHCLBHSA-N 0.000 description 1
WBYOCCGHKAPLST-VZGOPMHCSA-N (3s)-3-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-6-amino-2-[[2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2,5-diamino-5-oxopentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-(4h-imidazol-4-yl)propanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]hexanoyl]amino]-3-sulfanylpro Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(N)=O)CC1C=NC=N1 WBYOCCGHKAPLST-VZGOPMHCSA-N 0.000 description 1
SJHPCNCNNSSLPL-NTMALXAHSA-N (4z)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)/N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-NTMALXAHSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
CYWHLOXWVAWMFO-UHFFFAOYSA-N 3-sulfanyl-1h-pyridine-2-thione Chemical compound SC1=CC=CN=C1S CYWHLOXWVAWMFO-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
SSQHYGLFYWZWDV-UVBJJODRSA-N Ala-Val-Trp Chemical compound CC(C)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O SSQHYGLFYWZWDV-UVBJJODRSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
201000003076 Angiosarcoma Diseases 0.000 description 1
208000012657 Atopic disease Diseases 0.000 description 1
206010004593 Bile duct cancer Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010005081 Bladder squamous cell carcinoma stage unspecified Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000005243 Chondrosarcoma Diseases 0.000 description 1
208000006332 Choriocarcinoma Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
HAYVTMHUNMMXCV-IMJSIDKUSA-N Cys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CS HAYVTMHUNMMXCV-IMJSIDKUSA-N 0.000 description 1
SSNJZBGOMNLSLA-CIUDSAMLSA-N Cys-Leu-Asn Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O SSNJZBGOMNLSLA-CIUDSAMLSA-N 0.000 description 1
VXLXATVURDNDCG-CIUDSAMLSA-N Cys-Lys-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CS)N VXLXATVURDNDCG-CIUDSAMLSA-N 0.000 description 1
XZFYRXDAULDNFX-UWVGGRQHSA-N Cys-Phe Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UWVGGRQHSA-N 0.000 description 1
HMWBPUDETPKSSS-DCAQKATOSA-N Cys-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CS)N)C(=O)N[C@@H](CCCCN)C(=O)O HMWBPUDETPKSSS-DCAQKATOSA-N 0.000 description 1
DSTWKJOBKSMVCV-UWVGGRQHSA-N Cys-Tyr Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DSTWKJOBKSMVCV-UWVGGRQHSA-N 0.000 description 1
MJOYUXLETJMQGG-IHRRRGAJSA-N Cys-Tyr-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MJOYUXLETJMQGG-IHRRRGAJSA-N 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
102100033417 Glucocorticoid receptor Human genes 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000017278 Glutaredoxin Human genes 0.000 description 1
108050005205 Glutaredoxin Proteins 0.000 description 1
108010063907 Glutathione Reductase Proteins 0.000 description 1
102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000001258 Hemangiosarcoma Diseases 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
102000002397 Kinins Human genes 0.000 description 1
108010093008 Kinins Proteins 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
IIKJNQWOQIWWMR-CIUDSAMLSA-N Leu-Cys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)N IIKJNQWOQIWWMR-CIUDSAMLSA-N 0.000 description 1
WMTOVWLLDGQGCV-GUBZILKMSA-N Leu-Glu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N WMTOVWLLDGQGCV-GUBZILKMSA-N 0.000 description 1
UBZGNBKMIJHOHL-BZSNNMDCSA-N Leu-Leu-Phe Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 UBZGNBKMIJHOHL-BZSNNMDCSA-N 0.000 description 1
GCXGCIYIHXSKAY-ULQDDVLXSA-N Leu-Phe-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GCXGCIYIHXSKAY-ULQDDVLXSA-N 0.000 description 1
MAXILRZVORNXBE-PMVMPFDFSA-N Leu-Phe-Trp Chemical compound C([C@H](NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 MAXILRZVORNXBE-PMVMPFDFSA-N 0.000 description 1
VUBIPAHVHMZHCM-KKUMJFAQSA-N Leu-Tyr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 VUBIPAHVHMZHCM-KKUMJFAQSA-N 0.000 description 1
206010024305 Leukaemia monocytic Diseases 0.000 description 1
208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
208000007054 Medullary Carcinoma Diseases 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
NPLGQVKZFGJWAI-QWHCGFSZSA-N Phe-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O NPLGQVKZFGJWAI-QWHCGFSZSA-N 0.000 description 1
GNZCMRRSXOBHLC-JYJNAYRXSA-N Phe-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N GNZCMRRSXOBHLC-JYJNAYRXSA-N 0.000 description 1
208000007452 Plasmacytoma Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
TUYWCHPXKQTISF-LPEHRKFASA-N Pro-Cys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N2CCC[C@@H]2C(=O)O TUYWCHPXKQTISF-LPEHRKFASA-N 0.000 description 1
YKQNVTOIYFQMLW-IHRRRGAJSA-N Pro-Cys-Tyr Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H]1NCCC1)C1=CC=C(O)C=C1 YKQNVTOIYFQMLW-IHRRRGAJSA-N 0.000 description 1
AFWBWPCXSWUCLB-WDSKDSINSA-N Pro-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H]1CCC[NH2+]1 AFWBWPCXSWUCLB-WDSKDSINSA-N 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
GVMXJJAJLIEASL-ZJDVBMNYSA-N Thr-Pro-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVMXJJAJLIEASL-ZJDVBMNYSA-N 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
CGWAPUBOXJWXMS-HOTGVXAUSA-N Tyr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 CGWAPUBOXJWXMS-HOTGVXAUSA-N 0.000 description 1
MFEVVAXTBZELLL-GGVZMXCHSA-N Tyr-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MFEVVAXTBZELLL-GGVZMXCHSA-N 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
108010047495 alanylglycine Proteins 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
208000002399 aphthous stomatitis Diseases 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
201000007180 bile duct carcinoma Diseases 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
201000006598 bladder squamous cell carcinoma Diseases 0.000 description 1
208000003362 bronchogenic carcinoma Diseases 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
201000007455 central nervous system cancer Diseases 0.000 description 1
208000025997 central nervous system neoplasm Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
208000006990 cholangiocarcinoma Diseases 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
229910000365 copper sulfate Inorganic materials 0.000 description 1
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
208000002445 cystadenocarcinoma Diseases 0.000 description 1
108010060199 cysteinylproline Proteins 0.000 description 1
108010069495 cysteinyltyrosine Proteins 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
238000001514 detection method Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000002327 eosinophilic effect Effects 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
208000024711 extrinsic asthma Diseases 0.000 description 1
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000002737 fuel gas Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000003827 glycol group Chemical group 0.000 description 1
108010050848 glycylleucine Proteins 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical compound FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
102000055608 human beta subunit (81-95) follicle stimulating hormone Human genes 0.000 description 1
108700026359 human beta subunit (81-95) follicle stimulating hormone Proteins 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000003259 immunoinhibitory effect Effects 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000002664 inhalation therapy Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
235000021109 kimchi Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
206010024627 liposarcoma Diseases 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
208000012804 lymphangiosarcoma Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
201000006894 monocytic leukemia Diseases 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
208000001611 myxosarcoma Diseases 0.000 description 1
CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
208000007538 neurilemmoma Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
229960002969 oleic acid Drugs 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
230000033116 oxidation-reduction process Effects 0.000 description 1
208000004019 papillary adenocarcinoma Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
108010031719 prolyl-serine Proteins 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
206010039667 schwannoma Diseases 0.000 description 1
230000007017 scission Effects 0.000 description 1
201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
239000007921 spray Substances 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
201000010965 sweat gland carcinoma Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
238000012353 t test Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000012360 testing method Methods 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
239000000724 thymus hormone Substances 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
206010044412 transitional cell carcinoma Diseases 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
208000010576 undifferentiated carcinoma Diseases 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

SK467-97A 1994-10-14 1995-10-06 New peptides with immunomodulatory effects, preparation method thereof, pharmaceutical compositions containing them and their use SK46797A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9403526A SE9403526D0 (sv)	1994-10-14	1994-10-14	New Peptides
PCT/SE1995/001151 WO1996011943A1 (en)	1994-10-14	1995-10-06	New peptides with immunomodulatory effects

Publications (1)

Publication Number	Publication Date
SK46797A3 true SK46797A3 (en)	1997-09-10

Family

ID=20395628

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK467-97A SK46797A3 (en)	1994-10-14	1995-10-06	New peptides with immunomodulatory effects, preparation method thereof, pharmaceutical compositions containing them and their use

Country Status (20)

Country	Link
US (2)	US6103697A (pt)
EP (1)	EP0783519A1 (pt)
JP (1)	JPH10507448A (pt)
AU (1)	AU705364B2 (pt)
BR (1)	BR9509345A (pt)
CA (1)	CA2201479A1 (pt)
CZ (1)	CZ111997A3 (pt)
EE (1)	EE9700087A (pt)
FI (1)	FI971499L (pt)
HU (1)	HUT77118A (pt)
IL (1)	IL115509A0 (pt)
IS (1)	IS4459A (pt)
MX (1)	MX9702666A (pt)
NO (1)	NO971625L (pt)
PL (1)	PL319631A1 (pt)
SE (1)	SE9403526D0 (pt)
SK (1)	SK46797A3 (pt)
TR (1)	TR199501255A2 (pt)
WO (1)	WO1996011943A1 (pt)
ZA (1)	ZA958140B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9403526D0 (sv)	1994-10-14	1994-10-14	Astra Ab	New Peptides
SE9501067D0 (sv)	1995-03-24	1995-03-24	Astra Ab	New peptides
CA2250707A1 (en) *	1996-04-12	1997-10-23	Astra Aktiebolag	Cysteine-containing or methionine-containing peptides with immunomodulatory effects
EP0914143A1 (en) *	1996-07-08	1999-05-12	Rhone-Poulenc Rorer Limited	Medicinal cyclosporin-a aerosol solution formulation
SE9603465D0 (sv) *	1996-09-23	1996-09-23	Astra Ab	New compounds
SE9603468D0 (sv) *	1996-09-23	1996-09-23	Astra Ab	New compounds
SE9603467D0 (sv) *	1996-09-23	1996-09-23	Astra Ab	New compounds
SE9603461D0 (sv) *	1996-09-23	1996-09-23	Astra Ab	New compounds
SE9603466D0 (sv) *	1996-09-23	1996-09-23	Astra Ab	New compounds
SE9603463D0 (sv) *	1996-09-23	1996-09-23	Astra Ab	New compounds
SE9603462D0 (sv) *	1996-09-23	1996-09-23	Astra Ab	New compounds
US20010049381A1 (en)	1997-06-04	2001-12-06	Gpl Nil Holdings, Inc.,	Pyrrolidine derivative hair growth compositions and uses
WO1999019347A1 (en) *	1997-10-10	1999-04-22	Astrazeneca Ab	Synthetic genes with immunomodulatory effects
JP2002516839A (ja) *	1998-06-03	2002-06-11	ジーピーアイエヌアイエルホールディングス，インコーポレイテッド	ピペコリン酸誘導体毛髪成長組成物およびその使用
RU2144374C1 (ru) *	1998-11-23	2000-01-20	Закрытое акционерное общество "ВАМ"	Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
JP4711520B2 (ja) *	2000-03-21	2011-06-29	日本ケミカルリサーチ株式会社	生理活性ペプチド含有粉末
US7265208B2 (en) *	2001-05-01	2007-09-04	The Regents Of The University Of California	Fusion molecules and treatment of IgE-mediated allergic diseases
US8080560B2 (en) *	2004-12-17	2011-12-20	3M Innovative Properties Company	Immune response modifier formulations containing oleic acid and methods
ES2388684T3 (es)	2005-04-25	2012-10-17	Cadila Pharmaceuticals Limited	Adyuvantes de vacunas
KR101363455B1 (ko) *	2011-09-09	2014-02-21	(주)케어젠	매트릭스 메탈로프로테아제 활성 억제 펩타이드 및 이의 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4585755A (en) *	1985-04-29	1986-04-29	Merck & Co., Inc.	Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents
US4822606A (en) *	1986-04-07	1989-04-18	Duke University	Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
AU1366088A (en)	1987-01-28	1988-08-24	Ortho Pharmaceutical Corporation	Immunosuppressive peptides and methods of use
FR2622700B1 (fr)	1987-10-30	1993-08-13	Aderegem	Proteine et ses fragments representant l'expression specifique du gene ps2 des cancers du sein, anticorps obtenus a partir de ladite proteine et/ou de ses fragments, leurs applications a la detection et au diagnostic de cancers du sein
EP0341603A3 (en) *	1988-05-09	1990-07-04	Abbott Laboratories	Atrial peptide derivatives
US5223485A (en) *	1989-01-31	1993-06-29	Abbott Laboratories	Anaphylatoxin-receptor ligands
JP2596466B2 (ja)	1990-03-03	1997-04-02	アサヒビール株式会社	ダニの主要アレルゲンの還伝情報を有するｄｎａおよび該アレルゲンの製造方法
JP3592709B2 (ja)	1990-09-11	2004-11-24	インスティテュート・フォー・チャイルド・ヘルス・リサーチ	ダーマトファゴイデス（家塵ダニ）のアレルゲンのクローニングおよびシークエンシング
AU2296792A (en) *	1991-06-28	1993-01-25	Corvas International, Inc.	Novel inhibitors of platelet aggregation
JP2657861B2 (ja)	1991-09-17	1997-09-30	アサヒビール株式会社	ダニ主要アレルゲンの製造方法
KR100260342B1 (ko)	1991-10-16	2000-07-01	스타세이 엘. 첸링	더마토파고이드로 부터 유래된 알레르겐의 t세포 에피토프
JP3149033B2 (ja)	1991-10-30	2001-03-26	アサヒビール株式会社	ダニ主要アレルゲンＤｅｒｆＩＩ中のペプチド
JP3908271B2 (ja)	1993-03-05	2007-04-25	エピミューン，インコーポレイティド	Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
IL106214A (en) *	1993-07-01	1998-12-06	Yeda Res & Dev	Thf-gamma2 analogs and pharmaceutical compositions comprising them
JPH07215996A (ja)	1994-01-31	1995-08-15	Torii Yakuhin Kk	ダニアレルゲンのｂ細胞エピトープ
DK0769054T3 (da)	1994-07-05	2000-11-13	Steeno Res Group As	Immunmodulatorer
SE9403526D0 (sv)	1994-10-14	1994-10-14	Astra Ab	New Peptides

1994
- 1994-10-14 SE SE9403526A patent/SE9403526D0/xx unknown
1995
- 1995-09-27 ZA ZA958140A patent/ZA958140B/xx unknown
- 1995-10-03 IL IL11550995A patent/IL115509A0/xx unknown
- 1995-10-06 CA CA002201479A patent/CA2201479A1/en not_active Abandoned
- 1995-10-06 PL PL95319631A patent/PL319631A1/xx unknown
- 1995-10-06 EP EP95934921A patent/EP0783519A1/en not_active Withdrawn
- 1995-10-06 EE EE9700087A patent/EE9700087A/xx unknown
- 1995-10-06 SK SK467-97A patent/SK46797A3/sk unknown
- 1995-10-06 AU AU37133/95A patent/AU705364B2/en not_active Ceased
- 1995-10-06 HU HU9702044A patent/HUT77118A/hu unknown
- 1995-10-06 FI FI971499A patent/FI971499L/fi unknown
- 1995-10-06 JP JP8513146A patent/JPH10507448A/ja active Pending
- 1995-10-06 BR BR9509345A patent/BR9509345A/pt not_active Application Discontinuation
- 1995-10-06 WO PCT/SE1995/001151 patent/WO1996011943A1/en not_active Ceased
- 1995-10-06 CZ CZ971119A patent/CZ111997A3/cs unknown
- 1995-10-06 MX MX9702666A patent/MX9702666A/es unknown
- 1995-10-06 US US08/836,480 patent/US6103697A/en not_active Expired - Fee Related
- 1995-10-12 TR TR95/01255A patent/TR199501255A2/xx unknown
1997
- 1997-04-08 IS IS4459A patent/IS4459A/is unknown
- 1997-04-09 NO NO971625A patent/NO971625L/no unknown
2000
- 2000-05-01 US US09/562,897 patent/US6228374B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU705364B2 (en)	1999-05-20
TR199501255A2 (tr)	1996-06-21
FI971499A7 (fi)	1997-06-10
FI971499A0 (fi)	1997-04-10
WO1996011943A1 (en)	1996-04-25
BR9509345A (pt)	1997-11-25
NO971625L (no)	1997-05-30
EE9700087A (et)	1997-10-15
CA2201479A1 (en)	1996-04-25
AU3713395A (en)	1996-05-06
JPH10507448A (ja)	1998-07-21
NO971625D0 (no)	1997-04-09
SE9403526D0 (sv)	1994-10-14
ZA958140B (en)	1997-06-27
CZ111997A3 (en)	1997-12-17
IL115509A0 (en)	1996-05-14
FI971499L (fi)	1997-06-10
EP0783519A1 (en)	1997-07-16
MX9702666A (es)	1997-06-28
HUT77118A (hu)	1998-03-02
PL319631A1 (en)	1997-08-18
US6228374B1 (en)	2001-05-08
IS4459A (is)	1997-04-08
US6103697A (en)	2000-08-15

Publication	Publication Date	Title
SK46797A3 (en)	1997-09-10	New peptides with immunomodulatory effects, preparation method thereof, pharmaceutical compositions containing them and their use
JP3266311B2 (ja)	2002-03-18	新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
JP2514518B2 (ja)	1996-07-10	ヘプタペプチドおよびオクタペプチドのソマトスタチン類似アミド誘導体、それを含有する抗腫瘍剤
IE41510B1 (en)	1980-01-16	Peptides having lh-rh/fsh-rh activity and proces for their manufacture
CA2399187C (en)	2011-04-19	Kahalalide compounds
CA3073806A1 (en)	2019-03-14	Opioid agonist peptides and uses thereof
WO2004020462A1 (ja)	2004-03-11	Ｃｘｃｒ４拮抗薬およびその用途
JPH03504013A (ja)	1991-09-05	Ｔ細胞ヘルパー活性を有するペプチド
JP3178835B2 (ja)	2001-06-25	新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
HU203563B (en)	1991-08-28	Process for producing opioid-polypeptides and pharmaceutical compositions containing them
MXPA97002666A (en)	1997-06-01	New peptides with immunoregulated effects
JPWO1992004374A1 (ja)	1992-09-03	新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
AU641366B2 (en)	1993-09-23	Peptide compounds
JPH02500517A (ja)	1990-02-22	ペプチド化合物
CA2173939C (en)	2002-08-27	Oligopeptides derived from c-reactive protein fragments
US4684622A (en)	1987-08-04	Compositions and methods for producing vasodilation and antioxytocic activity
CN1781933B (zh)	2011-07-20	胸腺素α1活性片段环肽类似物及其聚乙二醇化衍生物
US4599324A (en)	1986-07-08	V1-vasopressin antagonists
HU201964B (en)	1991-01-28	Process for producing peptides inhibiting maturation of t-lymphocytes and activity of macrophages, as well as pharmaceutical compositions comprising same
EP0269389A2 (en)	1988-06-01	Peptides
JP4781621B2 (ja)	2011-09-28	Ｃｘｃｒ４拮抗薬およびその用途
CA2098535A1 (en)	1993-12-19	Linear peptides
NZ251969A (en)	1997-12-19	Cyclic hexapeptide derivatives and analogs and compositions thereof
CN119684408A (zh)	2025-03-25	一种高酶稳定性和抗炎活性的抗炎肽及其制备方法和应用
CA3017824C (en)	2025-09-23	Conjugates of tacrolimus, their compositions, and their uses